the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Breast Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB17-0716 Hahn, Olwen A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer Details
IRB17-1219 Nanda, Rita An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments Details
IRB17-0481 Nanda, Rita A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) Details
CIRB17-0041 Nanda, Rita S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Details
CIRB16-1695 Hahn, Olwen A011502: A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer: The ABC Trail Details
CIRB16-1609 Hahn, Olwen A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III study Details
CIRB16-0822 Hahn, Olwen Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Details
IRB15-1308 Hahn, Olwen PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer study Details
CIRB15-0239 Chmura, Steven NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Details
CIRB14-1036 Hahn, Olwen NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Details
CIRB14-0810 Chmura, Steven NSABP-B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Details
IRB13-1365 Jaskowiak, Nora A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy Details
Phase II
Study No PI Title
IRB17-0721 Nanda, Rita Phase II Study of Pembrolizumab and Mifepristone in Patients with Advanced HER2-negative Breast Cancer Details
CIRB17-1471 Nanda, Rita A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP inhibition (veliparib; ABT-888) and Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) Either alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) Details
IRB17-0602 Hahn, Olwen Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Details
IRB17-0711 Nanda, Rita A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects with Advanced or Metastatic Solid Tumors (Stage 1 and Stage 2 of Phase 2) Details
CIRB17-0921 Bao, Jean A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery Details
IRB16-0403 Nanda, Rita A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Details
CIRB16-1609 Hahn, Olwen A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III study Details
CIRB16-1399 Hahn, Olwen S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
CIRB15-0239 Chmura, Steven NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Details
IRB14-0424 Nanda, Rita A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer Details
10-183-B Nanda, Rita Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 Trial) Details
Phase I
Study No PI Title
IRB17-1403 Nanda, Rita An Open Label Study of SC 005 in Subjects with Triple Negative Breast Cancer (TNBC) Details
IRB17-0711 Nanda, Rita A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects with Advanced or Metastatic Solid Tumors (Stage 1 and Stage 2 of Phase 2) Details
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies Details
IRB16-1383 Nanda, Rita A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer Details
IRB16-0538 Luke, Jason A Multi-Center, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies Whose Disease has Progressed on PD-1 or PD-L1 Immune Checkpoint Inhibitors Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
IRB15-1767 Luke, Jason A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers Details
IRB15-1130 Chmura, Steven Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details
IRB14-0987 Patel, Jyoti A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors Details
Others
Study No PI Title
IRB16-1410 Abe, Hiroyuki MR Images to Predict Breast Lesions to be Benign or Malignant in Order to Reduce Unnecessary Biopsy
IRB17-0778 Nanda, Rita A pilot study to characterize the microbiome of triple-negative breast cancer patients
IRB16-0400 Giger, Maryellen Retrospective Database and Analysis of Breast Cancer Radiomics and Imaging Genomics
IRB16-0396 Schacht, David Development and Testing of an Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening = A Pilot Study
IRB16-0593 Abe, Hiroyuki Virtual Pathology: 9.4 Telsa MRI Evaluation of Breast Specimens
IRB14-0461 Karczmar, Gregory Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density
10-487-A O'Donnell, Peter The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing Details
15837A Chmura, Steven A Long Term Investigation of Curative Treatment in Breast Cancer Patients
9127 Karczmar, Gregory Improved MRi Images of Breast Lesions (not all cancer patients)


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .